Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
J Comp Eff Res
; 8(2): 81-90, 2019 01.
Article
em En
| MEDLINE
| ID: mdl-30547675
ABSTRACT
Aim & methods:
A retrospective study using the IBM Explorys Universe Database assessed the risk of gastrointestinal events (enterocolitis or diarrhea) among melanoma and lung cancer patients treated with ipilimumab and nivolumab combination or monotherapy. Results &conclusion:
There were 904 melanoma patients (607 ipilimumab, 140 nivolumab and 157 combo) and 1641 lung cancer patients (68 ipilimumab, 1542 nivolumab and 31 combo). Approximately, 37% of lung patients and 46% of melanoma patients experienced at least one adverse event. After adjusting for covariates, patients receiving combination therapy were more likely to have a gastrointestinal event compared with ipilimumab monotherapy patients (melanoma hazard ratio 1.54; 95% CI 1.06-2.25; lung hazard ratio 2.93; 95% CI 1.09-7.89).Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
3_ND
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Ipilimumab
/
Antineoplásicos Imunológicos
/
Nivolumabe
/
Gastroenteropatias
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Comp Eff Res
Ano de publicação:
2019
Tipo de documento:
Article